Suzuki C, Kenzaka T. Laninamivir-induced ischemic enterocolitis: A case report. World J Clin Cases 2022; 10(9): 2864-2870 [PMID: 35434102 DOI: 10.12998/wjcc.v10.i9.2864]
Corresponding Author of This Article
Tsuneaki Kenzaka, PhD, Professor, Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, 2-1-5, Arata-cho, Hyogo-ku, Kobe, Hyogo 652-0032, Japan. smile.kenzaka@jichi.ac.jp
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Mar 26, 2022; 10(9): 2864-2870 Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2864
Laninamivir-induced ischemic enterocolitis: A case report
Chihiro Suzuki, Tsuneaki Kenzaka
Chihiro Suzuki, Tsuneaki Kenzaka, Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Tanba 669-3495, Japan
Tsuneaki Kenzaka, Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, Kobe 652-0032, Japan
Author contributions: Suzuki C managed the case and redaction and correction of the manuscript; Kenzaka T assisted with redaction, correction, and reconstruction of the manuscript; All authors read and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Conflict-of-interest statement: The authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist statement, and the manuscript was prepared and revised according to the CARE Checklist statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tsuneaki Kenzaka, PhD, Professor, Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, 2-1-5, Arata-cho, Hyogo-ku, Kobe, Hyogo 652-0032, Japan. smile.kenzaka@jichi.ac.jp
Received: September 10, 2021 Peer-review started: September 10, 2021 First decision: October 25, 2021 Revised: October 29, 2021 Accepted: February 12, 2022 Article in press: February 12, 2022 Published online: March 26, 2022 Processing time: 193 Days and 0.3 Hours
Abstract
BACKGROUND
Neuraminidase inhibitor-associated acute hemorrhagic colitis is rare. We report a case of ischemic enterocolitis that was likely caused by laninamivir.
CASE SUMMARY
A 54-year-old female patient with influenza type A was administered 40 mg of laninamivir via inhalation once. On the same day, the patient experienced bloody stools and lower abdominal pain. A contrast-enhanced abdominal computed tomography showed edema-like changes from the descending colon to the sigmoid colon, which suggested ischemic enterocolitis.
CONCLUSION
We treated a patient with ischemic enterocolitis caused by laninamivir, a rare but similar symptom following the administration of oseltamivir.
Core Tip: Although a clear mechanism underlying oseltamivir-associated hemorrhagic enteritis/ischemic enterocolitis has not been elucidated, the simultaneous occurrence of the following two factors has been considered responsible for the condition: (1) Local angiospasm and vasculitis due to the effect of an allergic reaction to oseltamivir; and (2) Hypoperfusion in the intestinal tract due to the effect of dehydration caused by influenza. Laninamivir is considered to demonstrate the same mechanism as oseltamivir.
